한글목차

항우울제의 동향과 예측

세계의 항우울제 시장의 미래는 주요 우울 장애, 강박성 장애, 범불안장애, 공황장애 시장에서의 기회로 유망시되고 있습니다. 세계의 항우울제 시장은 2024-2030년 CAGR이 5.3%로, 2030년까지 추정 218억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 우울증, 강박 장애 및 기타 기분 장애의 유병률 증가와 정신건강에 대한 인식 증가입니다.

• Lucintel의 예측에 따르면 제품 유형별로는 선택적 세로토닌 재흡수 억제제가 주요 우울장애와 불안장애 증가로 인해 예측 기간 중 가장 큰 부문을 차지할 것으로 예상했습니다.
• 우울장애 카테고리에서 주요우울장애의 높은 유병률과 젊은 층의 우울증 치료 및 관리에 대한 인식이 높아짐에 따라 주요우울장애가 가장 큰 부문을 차지할 것으로 보입니다.
• 북미는 우울증 환자 증가, 노령 인구의 급격한 증가, 주요 기업의 진출로 인해 예측 기간 중 가장 규모가 큰 지역으로 남을 것으로 보입니다.

항우울제 시장의 전략적 성장 기회

항우울제 시장의 성장 기회는 다양한 용도를 통해 제공됩니다. 이러한 기회를 파악하고 활용하면 시장 개척이 비약적으로 발전하고 시장 규모가 확대될 수 있습니다.

• 신흥 시장 확대: 신흥 국가 시장에서 정신질환에 대한 인식이 높아지면서 특히 아시아와 아프리카에서 항우울제 시장이 더욱 확대될 것입니다. 제품의 현지 적합성 및 접근성 개선은 이들 지역에서 시장 침투를 촉진할 것입니다.
• 디지털 통합 솔루션: 모바일 앱, 원격의료 플랫폼 등 기존 항우울제와 함께 사용하면 환자의 참여와 순응도를 높일 수 있습니다. 완전한 치료를 가능하게 합니다.
• 맞춤형 치료: 맞춤 의료에는 약물의 효과를 높이고 환자의 만족도를 높이기 위한 유전자 검사가 포함될 수 있습니다. 맞춤의료에 대한 투자는 항우울제 개발에 새로운 초점을 제공할 수 있습니다.
• 혁신적 약물전달: 새로운 서방형 제제 및 약물전달 옵션은 치료 결과와 순응도를 개선하기 위한 새로운 지평을 열어줍니다.
• 파트너십 및 협업: 기술 기업 및 연구 기관과의 전략적 파트너십은 혁신을 촉진하고 항우울제의 새로운 치료법을 보다 효율적으로 시장에 출시할 수 있도록 돕습니다.

실시간에 이러한 전략적 성장은 항우울제 시장을 재정의하고 혁신적인 치료, 환자 치료 강화 및 시장 접근성 확대를 가져올 것입니다. 치료와 이러한 기회에 대한 접근은 시장에서 관찰되는 효과와 높은 수준의 발전을 더욱 향상시킬 수 있습니다.

항우울제 시장 성장 촉진요인 및 과제

항우울제 시장에는 성장과 시장 자체에 영향을 미치는 다양한 촉진요인과 과제가 있습니다. 이러한 요인을 이해하면 이 시장을 효과적으로 탐색할 수 있습니다.

항우울제 시장 성장 촉진요인은 다음과 같습니다.

• 기술의 발전: 제약 및 생명공학 산업의 혁신적인 발견은 새로운 항우울제의 도입을 촉진하고 있습니다. 뇌 화학 및 유전자 마커에 대한 지식이 증가함에 따라 보다 효과적이고 특정 증상에 초점을 맞춘 치료법이 개발되고 있습니다.
• 정신건강에 대한 인식 증가: 정신건강 문제에 대한 인식과 수용 증가는 항우울제 수요를 촉진하는 주요 요인입니다. 공교육과 낙인 제거 캠페인은 부정적인 인식을 줄이고 더 많은 사람들이 치료를 받도록 유도하고 있습니다.
• 규제 변화: 새로운 항우울제가 시장에 진입하는 한편, 승인, 새로운 항우울제 및 간소화되는 프로세스와 관련된 규제 프레임워크의 변화도 시장 역학 및 의약품 개발 일정에 영향을 미치고 있습니다.
• 우울증 유병률 증가: 전 세계 우울증 유병률 증가는 항우울제 치료에 대한 수요를 계속 증가시킬 것입니다. 라이프스타일 변화, 경제적 압박, 사회적 고립과 같은 요인이 이에 기여합니다.
• R&D 투자: R&D에 대한 투자는 항우울제 치료의 혁신을 촉진합니다. 세계 주요 기업과 연구 기관은 새로운 약물 및 기타 치료법 개발에 지속적으로 집중하고 있습니다.

항우울제 시장이 해결해야 할 과제는 다음과 같습니다.

• 높은 개발 비용: 신규 항우울제 개발 비용이 높기 때문에 소규모 기업 시장 진입이 제한되고 그 결과 가격이 상승합니다. 이는 의약품의 구매 용이성, 접근성에 영향을 미칠 수밖에 없습니다.
• 복잡한 규제 환경: 규제 당국의 개입과 승인 기간이 길어지면서 새로운 항우울제 도입이 지연되고 있습니다. 이러한 규제적 장애물을 극복하는 것은 제약사에게 큰 과제 중 하나입니다.
• 부작용 및 효능 문제: 부작용에 대한 우려와 환자 집단에 따른 효능의 편차는 새로운 항우울제의 수용성과 유용성을 떨어뜨릴 수 있습니다. 이러한 문제를 해결하는 것은 환자 결과를 개선하고 시장에서 수용성을 높이기 위해 중요합니다.

기술적, 경제적, 규제적 요인들이 서로 영향을 미치고받으며 항우울제 시장을 특징짓는 복잡한 시장 성장 촉진요인과 과제를 형성하고 있습니다. 이러한 요인들은 기술 발전과 인지도 향상을 통해 시장 성장을 지속적으로 지원해 왔지만, 높은 개발 비용과 규제 장벽과 같은 과제를 던져주기도 했습니다. 변화하는 항우울제 시장을 성공적으로 항해하기 위해서는 이러한 모든 역학을 고려해야 합니다.

목차

제1장 개요

제2장 세계의 항우울제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 항우울제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 항우울제 시장, 제품별
  • 삼환계 항우울제
  • 선택적 세라토닌 재흡수 저해제
  • 세라토닌·노르에피네프린 재흡수 저해제
  • 모노아민 산화효소 저해제
  • 세로토닌 길항제 및 재흡수 저해제
  • 기타
• 세계의 항우울제 시장, 우울증별
  • 주요 우울 장애
  • 강박성 장애
  • 범불안장애
  • 공황장애
  • 기타

제4장 2018-2030년 지역별 시장 동향과 예측 분석

• 지역별 세계 항우울제 시장
• 북미의 항우울제 시장
• 유럽의 항우울제 시장
• 아시아태평양의 항우울제 시장
• 기타 지역의 항우울제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 제품별 세계의 항우울제 시장의 성장 기회
  • 우울증별 세계의 항우울제 시장의 성장 기회
  • 지역별 세계 항우울제 시장의 성장 기회
• 세계의 항우울제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 항우울제 시장의 생산능력 확대
  • 세계의 항우울제 시장의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 기업 개요

• Alkermes
• AbbVie
• Eli Lilly
• F. Hoffmann-La Roche
• GlaxoSmithKline
• H. Lundbeck
• Merck

영문목차

Antidepressant Trends and Forecast

The future of the global antidepressant market looks promising with opportunities in the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder markets. The global antidepressant market is expected to reach an estimated $21.8 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are the rising prevalence of depression, obsessive-compulsive disorder, and other mood disorders, and the growing awareness about mental health.

• Lucintel forecasts that, within the product category, within the type category selective serotonin reuptake inhibitors will remain the largest segment over the forecast period due to the rising occurrence of major depressive disorder and anxiety disorders.
• Within the depressive disorder category, major depressive disorder will remain the largest segment due to the high prevalence of major depressive disorder and increasing awareness towards treatment and management of depression among the youth population.
• North America will remain the largest region over the forecast period due to increasing cases of depression, the surge in the geriatric population, and the presence of major players in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Antidepressant Market

Antidepressants have seen changes in technological, scientific, and social milieus. New trends are also emerging against this background. In this regard, understanding these trends is necessary for stakeholders to navigate the changing landscape.

• Personalized Medicine: The trend involves planning antidepressant treatment based on one's genetic makeup, which determines the effectiveness of medication and the potential for serious side effects. This has shifted how prescriptions are made and treatment is optimized.
• Digital Therapeutics: There is also an increasing integration of digital health tools, such as apps and web-based therapy, in new treatments. These adjunct tools enhance conventional therapies and improve adherence and outcomes.
• Ketamine and Psychedelic Therapies: Innovative treatments such as ketamine or psychedelic-based drugs are gaining attention due to their rapid efficacy in treating severe depression. These new treatments are being tested as possible solutions for resistant cases.
• Regenerative Medicine: In the field of regenerative medicine, including brain stimulation techniques like stem cell therapy, new directions are being explored in the development of antidepressants. These approaches aim to address the neurological issues underlying depression.
• Global Market Expansion: The market for antidepressants is expanding into more global territories, with developing economies growing at a remarkable pace. This is due to a wider recognition of mental health issues and increased efforts to improve healthcare accessibility in these regions.

Such emerging trends are shaping the antidepressant market with the introduction of novel treatment policies, improved personalized methods, and expanded global access. As these trends continue to evolve, they are likely to lead to better treatment outcomes and greater accessibility, which could significantly transform mental healthcare on a global scale.

This revision addresses issues like missing articles, redundant phrasing, awkward word choices, incomplete sentences, subject-verb agreement, and punctuation errors while keeping the original meaning and structure.

Recent Developments in the Antidepressant Market

Recent advancements in the antidepressant market reflect a dynamic landscape with new therapies, regulatory changes, and evolving patient needs. These developments are driving growth and innovation across the sector.

• New Therapies: The emergence of new antidepressant therapies, mainly using ketamine and psychedelics, may open new treatment options for patients with TRD and have the potential to change the typical pathways for drug development.
• Personalized Medicine: Research on genetics and biomarkers advances personalized antidepressant treatment. This paradigm focuses on tailoring therapies according to individual patient profiles to improve efficacy and minimize adverse side effects.
• Digital Health Integration: There is growing use of digital tools through technologies like teletherapy and mobile applications. The use of such digital tools is beginning to supplement traditional forms of antidepressant treatment for enhanced patient engagement and adherence.
• Changes in Regulations: Recent changes in regulatory norms have impacted the approval and release of new antidepressants in the market. The changes being made to regulations are more targeted toward providing a flexible drug development environment that can help increase patient access to new therapies at a faster pace.
• Growth in Regions: The market for antidepressants is expanding in the fast-growing regions of Asia-Pacific and Latin America. Increased awareness about mental health and improved healthcare infrastructure in these regions are driving this market.

These developments are significantly impacting the antidepressant market by introducing new treatment modalities, enhancing personalized care, and expanding global access. This evolving landscape is likely to improve patient outcomes and market dynamics.

Strategic Growth Opportunities for Antidepressant Market

Growth opportunities in the antidepressant market are presented through different applications. Identifying and capitalizing on such opportunities will drastically advance development and increase the size of the market.

• Emerging Market Expansion: Growing awareness of mental health disorders in developing markets will further expand the market for these drugs, particularly in Asia and Africa. Local adaptation of products and improved access can facilitate market penetration in these regions.
• Digitally Integrated Solutions: These can be used in conjunction with traditional antidepressants, such as mobile apps and telehealth platforms, to improve patient engagement and adherence. It provides a complete treatment.
• Tailor-Made Therapies: Personalized medicine may include genetic testing to enhance drug efficacy and improve patient satisfaction. Investment in personalized medicine can offer a new focus for the development of antidepressants.
• Innovative Drug Delivery: New extended-release preparations and drug delivery options open new frontiers for improving treatment outcomes and compliance.
• Partnerships and Collaborations: Strategic partnerships with technology companies and research institutions will drive innovation, bringing newer therapies for antidepressants to the market with greater efficiency.

In real-time, this strategic growth is redefining the antidepressant market and will deliver innovative therapies, enhanced patient care, and expanded market access. Treatment and access to these opportunities can further increase the effectiveness and the high degree of advancement observed in the market.

Antidepressant Market Driver and Challenges

The market for antidepressants has various drivers and challenges that affect growth and the market itself. Understanding these factors will help navigate this market effectively.

The factors responsible for driving the antidepressant market include:

• Technological Advancements: Innovative discoveries in the drug and biotechnological industries are driving the introduction of novel antidepressants. Increased knowledge about brain chemistry and genetic markers is leading to treatments that are more effective and targeted at specific conditions.
• Growing Awareness of Mental Health: The increasing awareness and acceptance of mental health issues is a major factor driving demand for antidepressants. Public education and de-stigmatizing campaigns are reducing negative perceptions and encouraging more people to seek treatment.
• Regulatory Changes: New antidepressants are entering the market while changing regulatory frameworks-those related to approvals, new antidepressants, and emerging streamlined processes-are also impacting market dynamics and drug development timelines.
• Increasing Prevalence of Depression: The growing prevalence of depression worldwide will continue to fuel demand for antidepressant therapies. Factors such as lifestyle changes, economic pressures, and social isolation contribute to this.
• Investment in Research and Development: Investment in R&D will drive innovation in antidepressant therapies. Leading pharmaceutical companies and research institutions worldwide are continuing to focus on developing new classes of drugs and other forms of treatment.

Challenges in the antidepressant market include:

• High Development Costs: The high cost of developing new antidepressants limits market entry for small companies and, consequently, raises prices. This undoubtedly affects the affordability and availability of medications.
• Complicated Regulatory Environment: Involving regulatory bodies and the increasing length of approval times continue to hinder or delay the introduction of new antidepressants. Overcoming these regulatory hurdles is one of the major challenges for any pharmaceutical company.
• Side Effects and Efficacy Issues: Concerns about side effects and variations in efficacy among different patient populations can reduce the acceptability and utility of new antidepressants. Addressing these issues is critical for better patient outcomes and market acceptance.

Technological, economic, and regulatory factors interact to form a complex web of drivers and challenges that characterize the antidepressant market. These factors have consistently supported market growth through technological advancements and increasing awareness, while also posing challenges such as high development costs and regulatory hurdles. All these dynamics must be considered to navigate and succeed in the changing landscape of antidepressants.

List of Antidepressant Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies antidepressant companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antidepressant companies profiled in this report include-

• Alkermes
• AbbVie
• Eli Lilly
• F. Hoffmann-La Roche
• GlaxoSmithKline
• H. Lundbeck
• Merck

Antidepressant by Segment

The study includes a forecast for the global antidepressant by product, depressive disorder, and region.

Antidepressant Market by Product [Analysis by Value from 2018 to 2030]:

• Tricyclic Antidepressants
• Selective Serotonin Reuptake Inhibitors
• Serotonin-Norepinephrine Reuptake Inhibitors
• Monoamine Oxidase Inhibitors
• Serotonin Antagonist & Reuptake Inhibitors
• Others

Antidepressant Market by Depressive Disorder [Analysis by Value from 2018 to 2030]:

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

Antidepressant Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Antidepressant Market

Antidepressants continue to be among the largest pharmaceutical markets in the world, driven by new developments in drug development and regulatory changes, coupled with emerging healthcare needs. Key regions are making tailored progress toward their unique challenges and opportunities. A snapshot of the recent news and developments across the United States, China, Germany, India, and Japan is provided below:

• United States: There is an increased focus on personalized medicine in the U.S. market, with new antidepressants targeting specific genetic markers. Other innovative treatments include ketamine-based therapies and digital therapeutics, where awareness and acceptance of mental health issues are high.
• China: As one of the most rapidly growing sectors in the country, increased awareness of mental health, along with various initiatives by the government to improve mental health services, is leading to the rise of local pharmaceutical companies. These companies are promoting the development of affordable antidepressants and catering to a large and diverse population base.
• Germany: Rapid advancements in SSRIs and new classes of antidepressants are taking place. Notably, there is an increasing drive to integrate digital health solutions and telemedicine to improve accessibility and foster greater patient engagement in treatment.
• India: The Indian market is growing, with a focus on affordability and accessibility. Generic antidepressants are on the rise, investments in mental health infrastructure are increasing, and innovations in drug delivery systems, along with local manufacturing, are central to the market's growth.
• Japan: Japan is focused on developing advanced drug formulations and improving the efficacy of existing antidepressants. The adoption of advanced innovative therapies is increasing in the market, including new interventions targeting specific neurotransmitter systems and new chemical compounds.

Features of the Global Antidepressant Market

Market Size Estimates: Antidepressant market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antidepressant market size by product, depressive disorder, and region in terms of value ($B).

Regional Analysis: Antidepressant market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, depressive disorders, and regions for the antidepressant market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antidepressant market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the antidepressant market by product (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others), depressive disorder (major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antidepressant Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Antidepressant Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Antidepressant Market by Product
  • 3.3.1: Tricyclic Antidepressants
  • 3.3.2: Selective Serotonin Reuptake Inhibitors
  • 3.3.3: Serotonin-Norepinephrine Reuptake Inhibitors
  • 3.3.4: Monoamine Oxidase Inhibitors
  • 3.3.5: Serotonin Antagonist & Reuptake Inhibitors
  • 3.3.6: Others
• 3.4: Global Antidepressant Market by Depressive Disorder
  • 3.4.1: Major Depressive Disorder
  • 3.4.2: Obsessive-Compulsive Disorder
  • 3.4.3: Generalized Anxiety Disorder
  • 3.4.4: Panic Disorder
  • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Antidepressant Market by Region
• 4.2: North American Antidepressant Market
  • 4.2.1: North American Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
  • 4.2.2: North American Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
• 4.3: European Antidepressant Market
  • 4.3.1: European Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
  • 4.3.2: European Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
• 4.4: APAC Antidepressant Market
  • 4.4.1: APAC Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
  • 4.4.2: APAC Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
• 4.5: ROW Antidepressant Market
  • 4.5.1: ROW Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
  • 4.5.2: ROW Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Antidepressant Market by Product
  • 6.1.2: Growth Opportunities for the Global Antidepressant Market by Depressive Disorder
  • 6.1.3: Growth Opportunities for the Global Antidepressant Market by Region
• 6.2: Emerging Trends in the Global Antidepressant Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Antidepressant Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antidepressant Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Alkermes
• 7.2: AbbVie
• 7.3: Eli Lilly
• 7.4: F. Hoffmann-La Roche
• 7.5: GlaxoSmithKline
• 7.6: H. Lundbeck
• 7.7: Merck